EFTR (eFFECTOR Therapeutics) קצב צמיחת רווח למניה בשנה הנוכחית

eFFECTOR Therapeutics (EFTR) develops selective protein translation regulators for lung cancer therapy, securing monopoly revenues through patents. The annual EPS growth rate clearly demonstrates the impact of the production and testing outsourcing model. However, the failure of clinical trials and the liquidation of the business have eliminated all defensive barriers. The value of 62.00 is the current reading of this metric, capturing the company's final development trajectory.

This metric measures the year-over-year growth rate of net earnings per share, reflecting the efficiency of capital generation. By analyzing the annual change in earnings per share, an investor can compare the market value of eFFECTOR Therapeutics (EFTR) with its financial statements. The absence of in-house facilities due to production outsourcing allows the company to optimize costs, which directly impacts the dynamics of this metric.